Jae Y. Ro, M.D., Ph.D.
Pathology Residency, Yonsei University, Seoul, Korea
After completing his fellowship at M. D. Anderson in the Department of Pathology; in 1985, he was named instructor in that department, and he was promoted to assistant professor, associate professor, and professor over the following 7 years. Dr. Ro left M. D. Anderson in 1998 to become Chairman and Director of the Department of Pathology at the Asan Medical Center, Ulsan University, Seoul, Korea, but returned the next year, assuming his past duties as Co-director of the Fellowship Training Program and Chief of Pulmonary and Mediastinal Pathology at the MD Anderson Cancer Center. He retired from MD Anderson in October 2001 and returned to the Asan Medical Center as a Chairman and Director of the Department of Pathology until he joined The Methodist Hospital in March, 2005.
Dr. Ro has served on many professional organizations, including the Korean-American Society of Pathology (for which he was chairman from 1996 to 1998), Korean Society of Pathology (for which he was vice-president from 2004-2005), American Society of Clinical Pathologists, College of American Pathologists, International Academy of Pathology and United States and Canadian Academy of Pathology. Dr. Ro has published over 500 papers in the highest quality peer reviewed journals and presented more than 400 abstracts at national and international scientific meetings. He also published one textbook and more than 20 book chapters and teaching manuals. He has served as a guest lecturer in the United States and abroad.
Dr. Ro’s main research interests include studies on pathogenesis of genitourinary tumors and lung tumors as well as prevention and determining prognostic factors. For these purposes, molecular and tissue microarray techniques have been used. The majority of these studies are translational research using surgical specimens submitted to The Methodist Hospital.
Genitourinary, lung, cancer, diagnosis, prognostic factors
Harvey AM, Grice B, Hamilton C, Truong LD, Ro JY, Ayala AG, Zhai QJ. Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b. Arch Pathol Lab Med. 2010 Jul;134(7):983-8.
Park J, Jeong IG, Bang JK, Cho YM, Ro JY, Hong JH, Ahn H, Kim CS. Preoperative Clinical and Pathological Characteristics of pT0 Prostate Cancer in Radical Prostatectomy. Korean J Urol. 2010 Jun;51(6):386-90.
Lee SY, Hwang I, Park YS, Gardner J, Ro JY. Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes? Int J Oncol. 2010 Jun;36(6):1461-7.
Rivera AL, Takei H, Zhai J, Shen SS, Ro JY, Powell SZ. Useful immunohistochemical markers in differentiating hemangioblastoma versus metastatic renal cell carcinoma. Neuropathology. 2010 Mar 30. [Epub ahead of print]
Lee JH, Kim HC, Kim CH, Ro JY: Hyperplasia of mesonephric remnant, epididymal type: a case report. Basic and Applied Pathol 2009;2 (2): 69-71.
Quiroga-Garza G, Khurana H, Shen S, Ayala AG, Ro JY. Sarcomatoid chromophobe renal cell carcinoma with heterologous sarcomatoid elements. A case report and review of the literature. Arch Pathol Lab Med. 2009 Nov;133(11):1857-60.
Park IH, Kwon Y, Ro JY, Lee KS, Ro J.Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue. Breast Cancer Res Treat. 2009 Nov 15. [Epub ahead of print]
Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS, Chung J, Lee KH. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol. 2009 Oct 15. [Epub ahead of print]
Chaux A, Tamboli P, Lezcano C, Ro J, Ayala A, Cubilla AL. Comparison of Subtypes of Penile Squamous Cell Carcinoma From High and Low Incidence Geographical Regions. Int J Surg Pathol. 2009 Jul 3. [Epub ahead of print]
Kim K, Pak PJ, Ro JY, Shin D, Huh SJ, Cho YM. Limited sampling of radical prostatectomy specimens with excellent preservation of prognostic parameters of prostate cancer. Arch Pathol Lab Med. 2009 Aug;133(8):1278-84.